Transasia Bio-Medicals Acquires Calbiotech Group
By Labmedica International staff writers
Posted on 01 May 2017
Image: The Calbiotech team (Photo courtesy of Calbiotech Group).
Transasia Bio-Medicals Ltd., an in-vitro diagnostic company, has acquired immunoassay developer and manufacturer Calbiotech Group of Companies through its subsidiary Erba Mannheim.
The Transasia- Erba Group offers a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urinalysis, diabetes monitoring, autoimmune & infectious disease monitoring, molecular diagnostics and microbiology. Calbiotech is a worldwide leader in immunoassay development and manufacturing and was the first company to introduce immunoassay kits in the US to detect antibodies against Zika virus in human blood. The acquisition of Calbiotech has strengthened the Transasia-Erba Group’s foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer and infectious diseases.
“Calbiotech Inc. and Dr. Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Globally, the immunology segment of the IVD industry is valued at around USD 15 billion,” said Mr. Suresh Vazirani, Chairman & Managing Director, Transasia-Erba Group. “Calbiotech’s expertise in immunoassay will allow us to strengthen our position in this high growth market and integrate their strong R&D program to further enhance the product development strategy of the Transasia- Erba Group.”